Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer
Status:
Terminated
Trial end date:
2016-06-21
Target enrollment:
Participant gender:
Summary
The purpose of this study was to determine if ruxolitinib, in combination with
Pemetrexed/Cisplatin and Pemetrexed Maintenance, is safe and effective in the treatment of
nonsquamous non-small cell lung cancer (NSCLC) that is Stage IIIB, Stage IV, or recurrent.